Nephrol Dial Transplant (2000) 15: 1993-1999
© 2000 European Renal Association-European Dialysis and Transplant Association
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
1 Departments of Nephrology, 2 Chest Medicine, and 3 Cardiology, Hôpital Erasme, Brussels, Belgium
Background. Some reports indicate that fibrates can induce renal dysfunction. However, the clinical characteristics of these episodes, and the respective nephrotoxicity of the four main fibrates used—namely, fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil—remain ill defined.
Methods. To better characterize this side-effect, we first reviewed the charts of 27 patients from our institution who developed an impairment of renal function during fibrate therapy. We next analysed the articles (n=24) that contained data on renal function in patients taking fibrates (n=2676).
Results. Among our 27 patients, 25 were on fenofibrate therapy, one was taking bezafibrate, and one ciprofibrate. Nineteen were recipients of solid-organ transplants (kidney recipients, n=15; heart or heart-lung recipients, n=4), and eight were non-transplanted patients with some impairment of renal function. Baseline plasma creatinine ranged from 0.9 to 2.9 mg/dl. It increased by a mean of 40% after the start of fibrate therapy. There was a concomitant increase of blood urea values (mean 36%) in most of the patients. Renal function returned to baseline in 18/24 patients after fibrate discontinuation. However, six patients, all transplant recipients, experienced a permanent increase in plasma creatinine. The incidence of fibrate-induced renal dysfunction among our series of kidney transplant recipients was 60%, as it occurred in 15 of the 25 patients who had ever taken fibrates. An increase of mean creatinine values during therapy was described in all papers on fenofibrate (n=7) and bezafibrate (n=8) (range 8–18% and 8–40% respectively), and in three of four papers dealing with ciprofibrate (range 6–16%). No significant renal impairment was described in any of the eight articles reporting data on gemfibrozil therapy.
Conclusion. Therapy with fenofibrate, bezafibrate, and ciprofibrate may induce renal dysfunction. Gemfibrozil appears to be devoid of this side-effect.
Keywords: creatinine; fibrate; gemfibrozil; literature review; transplantation; urea
Correspondence and offprint requests to: Daniel Abramowicz, Department of Nephrology, Hôpital Erasme, Route de Lennik 808, B-1070 Brussels, Belgium. E-mail: dabram{at}ueb.ac.be
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. R. McQuade, J. Griego, J. Anderson, and A. B. Pai Elevated serum creatinine levels associated with fenofibrate therapy Am. J. Health Syst. Pharm., January 15, 2008; 65(2): 138 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bays, J. McElhattan, and B. S Bryzinski A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 181 - 193. [Abstract] [PDF]
|
|
|
|
|
|
J. P. Wilding, I. Gause-Nilsson, and A. Persson Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 194 - 203. [Abstract] [PDF]
|
|
|
|
|
|
B. Goke, I. Gause-Nilsson, and A. Persson The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 204 - 213. [Abstract] [PDF]
|
|
|
|
 |
|
 S. E. Nissen, S. J. Nicholls, K. Wolski, D. C. Howey, E. McErlean, M.-D. Wang, E. V. Gomez, and J. M. Russo Effects of a Potent and Selective PPAR-{alpha} Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia: Two Randomized Controlled Trials JAMA, March 28, 2007; 297(12): 1362 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Levey Nondiabetic Kidney Disease N. Engl. J. Med., November 7, 2002; 347(19): 1505 - 1511. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Tsimihodimos, E. Bairaktari, M. Elisaf, J. M. Bargman, and J. Lipscombe Fibrate-induced increase in serum urea and creatinine levels Nephrol. Dial. Transplant., April 1, 2002; 17(4): 682 - 682. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Scholz-Pedretti, A. Gans, K.-F. Beck, J. Pfeilschifter, and M. Kaszkin Potentiation of TNF-{alpha}-Stimulated Group IIA Phospholipase A2 Expression by Peroxisome Proliferator-Activated Receptor {alpha} Activators in Rat Mesangial Cells J. Am. Soc. Nephrol., March 1, 2002; 13(3): 611 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lipscombe and J. M. Bargman Fibrate-induced increase in blood urea and creatinine Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1515 - 1515. [Full Text] [PDF]
|
|
|
|
|
|
V. Tsimihodimos, A. Kakafika, and M. Elisaf Fibrate treatment can increase serum creatinine levels Nephrol. Dial. Transplant., June 1, 2001; 16(6): 1301 - 1301. [Full Text] [PDF]
|
|